|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.34 | 89.43 | 104.26 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Operational & Financial Ratios | | | | | | Earnings Per Share (Rs) | -0.77 | -0.42 | -0.41 | -0.14 | -0.38 | CEPS(Rs) | -0.77 | -0.40 | -0.34 | -0.06 | -0.30 | DPS(Rs) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Book NAV/Share(Rs) | -1.67 | -0.90 | -0.47 | -0.06 | 0.07 | Tax Rate(%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Margin Ratios | | | | | | Core EBITDA Margin(%) | 0 | 0 | 0 | 0 | 0 | EBIT Margin(%) | 0 | 0 | 0 | 0 | 0 | Pre Tax Margin(%) | 0 | 0 | 0 | 0 | 0 | PAT Margin (%) | 0 | 0 | 0 | 0 | 0 | Cash Profit Margin (%) | 0 | 0 | 0 | 0 | 0 | Performance Ratios | | | | | | ROA(%) | -47.15 | -17.39 | -12.78 | -4.11 | -10.36 | ROE(%) | 0.00 | 0.00 | 0.00 | -2,869.33 | -144.20 | ROCE(%) | -52.60 | -27.96 | -27.33 | -8.82 | -19.67 | Asset Turnover(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Sales/Fixed Asset(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Working Capital/Sales(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Efficiency Ratios | | | | | | Fixed Capital/Sales(x) | 0 | 0 | 0 | 0 | 0 | Receivable days | 0 | 0 | 0 | 0 | 0 | Inventory Days | 0 | 0 | 0 | 0 | 0 | Payable days | 0 | 0 | 0 | 0 | 0 | Valuation Parameters | | | | | | PER(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | PCE(x) | -7.23 | -11.38 | 0.00 | -48.63 | -1.84 | Price/Book(x) | -3.34 | -5.08 | 0.00 | -49.71 | 7.71 | Yield(%) | 0.00 | 0.00 | 0 | 0.00 | 0.00 | EV/Net Sales(x) | 0 | 0 | 0 | 0 | 0 | EV/Core EBITDA(x) | -11.33 | -17.23 | -35.49 | -74.31 | -7.16 | EV/EBIT(x) | -11.33 | -16.31 | -29.32 | -34.56 | -5.74 | EV/CE(x) | 5.43 | 4.14 | 3.76 | 1.43 | 0.61 | M Cap / Sales | 0 | 0 | 0 | 0 | 0 | Growth Ratio | | | | | | Net Sales Growth(%) | 0 | 0 | 0 | 0 | -100.00 | Core EBITDA Growth(%) | -92.57 | -17.83 | -447.40 | 78.46 | 87.63 | EBIT Growth(%) | -82.20 | -2.92 | -208.09 | 62.89 | 92.52 | PAT Growth(%) | -82.26 | -2.98 | -202.11 | 63.83 | 93.01 | EPS Growth(%) | -82.26 | -2.98 | -202.08 | 63.82 | 93.01 | Financial Stability Ratios | | | | | | Total Debt/Equity(x) | -1.89 | -2.61 | -4.33 | -23.54 | 20.97 | Current Ratio(x) | 0.47 | 0.63 | 0.85 | 0.94 | 0.94 | Quick Ratio(x) | 0.47 | 0.63 | 0.85 | 0.94 | 0.94 | Interest Cover(x) | -1,088.65 | -1,698.31 | 0 | -50.52 | -21.58 | Total Debt/Mcap(x) | 0.57 | 0.51 | 0 | 0.47 | 2.72 |
|
|
|
|
|
|